Outcome of simultaneous liver–kidney transplantation in highly sensitized, crossmatch-positive patients

• Published in: Transplantation proceedings Vol. 35; no. 5; pp. 1861 - 1862
• Main Authors: Gutiérrez, A, Crespo, M, Mila, J, Torregrosa, J.V, Martorell, J, Oppenheimer, F
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.08.2003; Elsevier Science
• Subjects: Adult; Alanine Transaminase - blood; Aspartate Aminotransferases - blood; Biological and medical sciences; Female; Flow Cytometry; Histocompatibility Testing - methods; Humans; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - immunology; Kidney Transplantation - physiology; Liver Transplantation - immunology; Liver Transplantation - physiology; Liver, biliary tract, pancreas, portal circulation, spleen; Medical sciences; Middle Aged; Retrospective Studies; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the digestive system; Surgery of the urinary system; Treatment Outcome; Human; Prognosis; Digestive system; Liver; Concurrent; Transplantation; Homotransplantation; Kidney; Treatment; Urinary system; Combined surgery; Surgery; Graft
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/S0041-1345(03)00621-3

In simultaneous liver–kidney transplantation (SLKT), the liver has been described to protect the kidney from rejection, and acceptable results are possible despite a pretransplant positive crossmatch. At our center, 21 SLKT have been performed since 1993, 2 of them against a positive crossmatch. In this study we retrospectively analyzed two cases of SLKT after positive pretransplant crossmatch. Two highly sensitized women (30 and 52 years) with hepatic cirrhosis VHC on hemodialysis after a first KT failure were assessed. Pretransplant panel reactive antibodies (PRA) by complement dependent cytotoxicity NIH (CDC) were 81% and 99% respectively. Both patients received a SLKT. CM was performed at pretransplant and 24 and 48 hours posttransplant by CDC and by flow cytometry with double labeling with CD3-PE and antihuman IgG-FITC. Patients received ATG, cyclosporine, and prednisone therapy. CM was positive pretransplant by CDC and flow cytometry. At 48 hours, CDC became almost negative (10%–20% mortality) and flow cytometry became negative. One of the patients experienced an episode of acute rejection at 10 days posttransplant that resolved with steroid pulses. Both patients presently have working grafts 26 and 24 months posttransplant (Cr, 1.1 and 1.5 mg/dL; GOT, 34 and 14 IU/L; GTP, 29 and 12 IU/L; GGT, 9 and 66 IU/L). Our experience suggests that a positive crossmatch is not an absolute contraindication for SLKT. Good graft and patient survival rates are possible even among highly sensitized patients.